A Study of Dato-DXd in People With Breast Cancer

Full Title

A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HR-positive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-5157.

Protocol
26-163
Phase
Phase III (phase 3)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07205822